Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 5/20 | 0.44 |
| ▸ | PDCD1LG2 | Q9BQ51 | 1/20 | 0.39 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.39 |
| ▸ | DRD2 | P14416 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.35 |
| ▸ | COMT | P21964 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 2/20 | 0.35 |
| ▸ | RAB9A | P51151 | 2/20 | 0.35 |
| ▸ | KDM5A | P29375 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25666931 | 0.86 | PDCD1LG2 (0.38) | PIK3CDPDCD1LG2CD274DRD2EPHX2 | |
| SCHEMBL21739463 | 0.81 | PDCD1LG2 (0.41) | PDCD1LG2CD274DRD2EPHX2KDM5A | |
| SCHEMBL24711532 | 0.81 | PDCD1LG2 (0.41) | PDCD1LG2CD274DRD2EPHX2KDM5A | |
| SCHEMBL17722618 | 0.81 | PDCD1LG2 (0.41) | PDCD1LG2CD274DRD2EPHX2KDM5A | |
| SCHEMBL21322091 | 0.79 | PIK3CD (0.51) | PIK3CDPDCD1LG2CD274POLBNPC1 | |
| SCHEMBL17718802 | 0.77 | PDCD1LG2 (0.39) | PDCD1LG2CD274DRD2EPHX2KDM5A | |
| SCHEMBL3420965 | 0.77 | PARP2 (0.44) | PIK3CDNPC1RAB9AL3MBTL1 | |
| SCHEMBL21740359 | 0.75 | HRH3 (0.39) | PDCD1LG2CD274NPC1RAB9AKDM5A | |
| SCHEMBL21739118 | 0.75 | HRH3 (0.39) | PDCD1LG2CD274NPC1RAB9AKDM5A | |
| SCHEMBL8939416 | 0.75 | HRH3 (0.39) | PDCD1LG2CD274NPC1RAB9AKDM5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230143612-A1 | SUBSTITUTED 1,1'-BIPHENYL COMPOUNDS AND METHODS USING SAME | ARBUTUS BIOPHARMA CORP (US) | 2023-05-11 | — | — | US | disclosed |
| US-20230143612-A1 | SUBSTITUTED 1,1'-BIPHENYL COMPOUNDS AND METHODS USING SAME | ARBUTUS BIOPHARMA CORP (US) | 2023-05-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230143612-A1 | SUBSTITUTED 1,1'-BIPHENYL COMPOUNDS AND METHODS USING SAME | HAVCR2, HMBS, VHL | PIK3CD 2759/4885PDCD1LG2 225/4885CD274 75/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.